Key issues in the clinical management of gastrointestinal stromal tumors

An expert discussion

Robert G. Maki, Jean Yves Blay, George D. Demetri, Jonathan A. Fletcher, Heikki Joensuu, Javiermart In-Broto, Toshirou Nishida, Peter Reichardt, Patrick Schöffski, Jonathan Trent

Research output: Contribution to journalArticle

Abstract

After the revelation of kinase targeting with orally available small molecules, the use of imatinib in chronic myelogenous leukemia and in gastrointestinal stromal tumor (GIST) has now become commonplace and just two of many examples of the use of kinase inhibitors in cancer. In this article, we discuss important practice points that may impact upon questions of therapy of primary and metastatic GIST, with the hope that the questions addressed in this rare solid tumor can serve as examples of what can be achieved with kinase-directed therapies in other cancers. Wepresent cases that highlight some of the key issues in GIST management and afterward discuss both points of consensus and controversial issues in what is now recognizedas one of the most common forms of sarcoma.

Original languageEnglish (US)
Pages (from-to)823-830
Number of pages8
JournalOncologist
Volume20
Issue number7
DOIs
StatePublished - Jun 12 2015

Fingerprint

Gastrointestinal Stromal Tumors
Phosphotransferases
Neoplasms
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sarcoma
Therapeutics

Keywords

  • Carney-Stratakis syndrome
  • Gastrointestinal stromal tumor
  • GIST
  • Imatinib
  • KIT
  • PDGFRA
  • Regorafenib
  • SDH
  • Sunitinib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Maki, R. G., Blay, J. Y., Demetri, G. D., Fletcher, J. A., Joensuu, H., In-Broto, J., ... Trent, J. (2015). Key issues in the clinical management of gastrointestinal stromal tumors: An expert discussion. Oncologist, 20(7), 823-830. https://doi.org/10.1634/theoncologist.2014-0353

Key issues in the clinical management of gastrointestinal stromal tumors : An expert discussion. / Maki, Robert G.; Blay, Jean Yves; Demetri, George D.; Fletcher, Jonathan A.; Joensuu, Heikki; In-Broto, Javiermart; Nishida, Toshirou; Reichardt, Peter; Schöffski, Patrick; Trent, Jonathan.

In: Oncologist, Vol. 20, No. 7, 12.06.2015, p. 823-830.

Research output: Contribution to journalArticle

Maki, RG, Blay, JY, Demetri, GD, Fletcher, JA, Joensuu, H, In-Broto, J, Nishida, T, Reichardt, P, Schöffski, P & Trent, J 2015, 'Key issues in the clinical management of gastrointestinal stromal tumors: An expert discussion', Oncologist, vol. 20, no. 7, pp. 823-830. https://doi.org/10.1634/theoncologist.2014-0353
Maki RG, Blay JY, Demetri GD, Fletcher JA, Joensuu H, In-Broto J et al. Key issues in the clinical management of gastrointestinal stromal tumors: An expert discussion. Oncologist. 2015 Jun 12;20(7):823-830. https://doi.org/10.1634/theoncologist.2014-0353
Maki, Robert G. ; Blay, Jean Yves ; Demetri, George D. ; Fletcher, Jonathan A. ; Joensuu, Heikki ; In-Broto, Javiermart ; Nishida, Toshirou ; Reichardt, Peter ; Schöffski, Patrick ; Trent, Jonathan. / Key issues in the clinical management of gastrointestinal stromal tumors : An expert discussion. In: Oncologist. 2015 ; Vol. 20, No. 7. pp. 823-830.
@article{3a1005754de5474cbd94ebee255fd010,
title = "Key issues in the clinical management of gastrointestinal stromal tumors: An expert discussion",
abstract = "After the revelation of kinase targeting with orally available small molecules, the use of imatinib in chronic myelogenous leukemia and in gastrointestinal stromal tumor (GIST) has now become commonplace and just two of many examples of the use of kinase inhibitors in cancer. In this article, we discuss important practice points that may impact upon questions of therapy of primary and metastatic GIST, with the hope that the questions addressed in this rare solid tumor can serve as examples of what can be achieved with kinase-directed therapies in other cancers. Wepresent cases that highlight some of the key issues in GIST management and afterward discuss both points of consensus and controversial issues in what is now recognizedas one of the most common forms of sarcoma.",
keywords = "Carney-Stratakis syndrome, Gastrointestinal stromal tumor, GIST, Imatinib, KIT, PDGFRA, Regorafenib, SDH, Sunitinib",
author = "Maki, {Robert G.} and Blay, {Jean Yves} and Demetri, {George D.} and Fletcher, {Jonathan A.} and Heikki Joensuu and Javiermart In-Broto and Toshirou Nishida and Peter Reichardt and Patrick Sch{\"o}ffski and Jonathan Trent",
year = "2015",
month = "6",
day = "12",
doi = "10.1634/theoncologist.2014-0353",
language = "English (US)",
volume = "20",
pages = "823--830",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "7",

}

TY - JOUR

T1 - Key issues in the clinical management of gastrointestinal stromal tumors

T2 - An expert discussion

AU - Maki, Robert G.

AU - Blay, Jean Yves

AU - Demetri, George D.

AU - Fletcher, Jonathan A.

AU - Joensuu, Heikki

AU - In-Broto, Javiermart

AU - Nishida, Toshirou

AU - Reichardt, Peter

AU - Schöffski, Patrick

AU - Trent, Jonathan

PY - 2015/6/12

Y1 - 2015/6/12

N2 - After the revelation of kinase targeting with orally available small molecules, the use of imatinib in chronic myelogenous leukemia and in gastrointestinal stromal tumor (GIST) has now become commonplace and just two of many examples of the use of kinase inhibitors in cancer. In this article, we discuss important practice points that may impact upon questions of therapy of primary and metastatic GIST, with the hope that the questions addressed in this rare solid tumor can serve as examples of what can be achieved with kinase-directed therapies in other cancers. Wepresent cases that highlight some of the key issues in GIST management and afterward discuss both points of consensus and controversial issues in what is now recognizedas one of the most common forms of sarcoma.

AB - After the revelation of kinase targeting with orally available small molecules, the use of imatinib in chronic myelogenous leukemia and in gastrointestinal stromal tumor (GIST) has now become commonplace and just two of many examples of the use of kinase inhibitors in cancer. In this article, we discuss important practice points that may impact upon questions of therapy of primary and metastatic GIST, with the hope that the questions addressed in this rare solid tumor can serve as examples of what can be achieved with kinase-directed therapies in other cancers. Wepresent cases that highlight some of the key issues in GIST management and afterward discuss both points of consensus and controversial issues in what is now recognizedas one of the most common forms of sarcoma.

KW - Carney-Stratakis syndrome

KW - Gastrointestinal stromal tumor

KW - GIST

KW - Imatinib

KW - KIT

KW - PDGFRA

KW - Regorafenib

KW - SDH

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84936879733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936879733&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2014-0353

DO - 10.1634/theoncologist.2014-0353

M3 - Article

VL - 20

SP - 823

EP - 830

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 7

ER -